Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANI Refiles Cortrophin After Talks With FDA

Application Turned Down By FDA Last Year

Executive Summary

US-based ANI Pharmaceuticals has made manufacturing and API changes as part of its refiled package for Cortrophin Gel (corticotropin) for injection, which it hopes will be a “transformational opportunity.”

You may also be interested in...



Who’s Hired? ANI Pharma Strengthens Leadership With Three New Executives

ANI pharma strengthens leadership team by adding three new executives to accelerate future growth. While Coherus and Xbrane appoint new chief financial officers, Lupin and Beximco hire new independent directors. Sandoz is certified “Global Top Employer 2021” yet again by Top Employers Institute.

ANI CEO Przybyl To Depart After 11 Years

ANI Pharmaceuticals has been steered by former Akorn head Arthur Przybyl since March 2009. But he will bring the curtain down on his time with the company next month, as the company recruits his replacement ahead of a key branded product launch.

Small Cash Component Delaying Opioid Deal, Says ‘Optimistic’ Teva

Teva CEO Kåre Schultz has spoken at great length and in great detail about Teva’s ability to reach a proposed settlement in the US over allegations the firm helped fuel the opioid epidemic, revealing that a deal may be only 12 months away.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;